Class IC antiarrhythmic drugs, flecainide and pilsicainide, produce ST segment elevation simulating inferior myocardial ischemia

Journal of Cardiovascular Electrophysiology

Volumn 9, Issue 8, 1998, Pages 855-858

  Nakamura, Wako ^a   Segawa, Kazuhiko ^a   Ito, Hiroyuki ^a   Tanaka, Shugo ^a   Yoshimoto, Nobuo ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Class IC antiarrhythmic drugs; Electrocardiogram; Flecainide; Pilsicainide; ST segment elevation

Indexed keywords

ANTIARRHYTHMIC AGENT; DISOPYRAMIDE; FLECAINIDE; MEXILETINE; NIFEKALANT; PILSICAINIDE;

ADULT; ARTICLE; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIAGNOSTIC ERROR; HEART MUSCLE ISCHEMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RESPIRATORY FAILURE; ST SEGMENT ELEVATION;

EID: 0031867621     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.1998.tb00125.x     Document Type: Article

References (12)

1. Atarashi H, Inoue H, Hiejima K, et al: Conversion of recent-onset atrial fibrillation by a single oral dose of pilsicainide. Am J Cardiol 1996;78:694-697.
2. van Aubel KJJCM, Ruiter JH, Arnold AE, et al: Pseudo infarction ECG pattern occurring during intravenous treatment with flecainide acetate. Eur Heart J 1992;13:137-139.
3. Nakazato Y, Nakata Y, Yasuda M, et al: Safety and efficacy of oral flecainide acetate in patients with cardiac arrhythmias. Jpn Heart J 1997;38:379-385.
4. Kihara Y, Inoko M, Hatakeyama N, et al: Mechanisms of negative inotropic effects of class Ic antiarrhythmic agents: Comparative study of the effects of flecainide and pilsicainide on intracellular calcium handling in dog ventricular myocardium. J Cardiovasc Pharmacol 1996;27:42-51.
5. Isomoto S, Konoe A, Centurion OA, et al: Electrophysiological effects of MS-551 in humans: A class III antiarrhythmic agent. PACE 1995;18:2022-2027.
6. Krishnan SC, Antzelevitch C: Flecainide-induced arrhythmia in canine ventricular epicardium: Phase 2 reentry? Circulation 1993;87:562-572.
7. Antzelevitch C, Sicouri S, Litovsky SH, et al: Heterogeneity within the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells. Circ Res 1991;69:1427-1449.
8. Miyazaki T, Mitamura H, Miyoshi S, et al: Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 1996;27:1061-1070.
9. Chinushi M, Aizawa Y, Ogawa Y, et al: Discrepant drug action of disopyramide on ECG abnormalities and induction of ventricular arrhythmias in a patient with Brugada syndrome. J Electrocardiol 1997;30:133-136.
10. Sadanaga T, Ogawa S: Ischemia enhances use-dependent sodium channel blockade by pilsicainide, a class IC antiarrhythmic agent. J Am Coll Cardiol 1994;23: 1378-1381.
11. Ono K, Kiyosue T, Arita M: Isoproterenol, DBcAMP, and forskolin inhibit cardiac sodium current. Am J Physiol 1989;256:C1131-C1137.
12. Cragun KT, Johnson SB, Packer DL: β-adrenergic augmentation of flecainide-induced conduction slowing in canine Purkinje fibers. Circulation 1997;96:2701-2708.